

---

## Transtema - Brighter Times Ahead

Redeye maintains a positive view of Transtema following a Q2 beating our expectations. While the Q2 numbers were on the soft side as expected (yet better than expected), the most important takeaway is that the worst likely is over, and Transtema enters 2025 with a solid order backlog. Although we somewhat lower our expectations in Norway, we retain our positive view of 2025.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Transtema - Brighter Times Ahead](#)